A biodegradable drug delivery system for the treatment of postoperative inflammation

International Journal of Pharmaceutics

Volumn 352, Issue 1-2, 2008, Pages 240-247

  Eperon, S ^a   Bossy Nobs, L ^b   Petropoulos, I K ^a   Gurny, R ^b   Guex Crosier, Y ^a  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

Biodegradable polymer; Drug delivery; Intraocular lens; Rabbit; Triamcinolone

Indexed keywords

POLYGLACTIN; TRIAMCINOLONE ACETONIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AQUEOUS HUMOR; ARTICLE; BIOCOMPATIBILITY; BIODEGRADABILITY; CATARACT EXTRACTION; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG MECHANISM; DRUG RELEASE; IN VITRO STUDY; INFLAMMATORY CELL; LENS IMPLANT; MOLECULAR WEIGHT; NONHUMAN; POSTOPERATIVE INFLAMMATION; PRIORITY JOURNAL; RABBIT;

ANIMALS; ANTI-INFLAMMATORY AGENTS; AQUEOUS HUMOR; CATARACT EXTRACTION; CHEMISTRY, PHARMACEUTICAL; DELAYED-ACTION PREPARATIONS; DRUG CARRIERS; DRUG COMPOUNDING; INFLAMMATION; LACTIC ACID; LENS IMPLANTATION, INTRAOCULAR; LENSES, INTRAOCULAR; MODELS, ANIMAL; MOLECULAR WEIGHT; POLYGLYCOLIC ACID; PROSTHESIS DESIGN; RABBITS; SOLUBILITY; TECHNOLOGY, PHARMACEUTICAL; TRIAMCINOLONE ACETONIDE;

EID: 39549085728     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2007.10.054     Document Type: Article

References (37)

1. Adamis A.P., and Shima D.T. The role of vascular endothelial growth factor in ocular health and disease. Retina 25 (2005) 111-118
2. Ambati J., Ambati B.K., Yoo S.H., Ianchulev S., and Adamis A.P. Age-related macular degeneration: etiology, pathogenesis, and therapeutic strategies. Surv. Ophthalmol. 48 (2003) 257-293
3. Antcliff R.J., Spalton D.J., Stanford M.R., Graham E.M., Ffytche T.J., and Marshall J. Intravitreal triamcinolone for uveitic cystoid macular edema: an optical coherence tomography study. Ophthalmology 108 (2001) 765-772
4. Audren F., Tod M., Massin P., Benosman R., Haouchine B., Erginay A., Caulin C., Gaudric A., and Bergmann J.F. Pharmacokinetic-pharmacodynamic modeling of the effect of triamcinolone acetonide on central macular thickness in patients with diabetic macular edema. Invest. Ophthalmol. Vis. Sci. 45 (2004) 3435-3441
5. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72 (1976) 248-254
6. Cahill M.T., and Jaffe G.J. Intraocular sustained-release drug delivery in uveitis. In: Jaffe G.J., Ashton P., and Pearson P.A. (Eds). Intraocular Drug Delivery (2006), Taylor & Francis Group, New York 265-278
7. Chang D.F., Garcia I.H., Hunkeler J.D., and Minas T. Phase II results of an intraocular steroid delivery system for cataract surgery. Ophthalmology 106 (1999) 1172-1177
8. Ciulla T.A., Walker J.D., Fong D.S., and Criswell M.H. Corticosteroids in posterior segment disease: an update on new delivery systems and new indications. Curr. Opin. Ophthalmol. 15 (2004) 211-220
9. El Harazi S.M., and Feldman R.M. Control of intra-ocular inflammation associated with cataract surgery. Curr. Opin. Ophthalmol. 12 (2001) 4-8
10. Eyetech Study Group. Anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration: phase II study results. Ophthalmology 110 (2003) 979-986
11. Felt-Baeyens O., Eperon S., Mora P., Limal D., Sagodira S., Breton P., Simonazzi B., Bossy-Nobs L., Guex-Crosier Y., and Gurny R. Biodegradable scleral implants as new triamcinolone acetonide delivery systems. Int. J. Pharm. 322 (2006) 6-12
12. Hankinson S.-E. Epidemiology of age-related cataract. In: Albert D.M., Jakobiec F.A., Azar D.T., and Gragoudas E.S. (Eds). Principles and Practice of Ophthalmology vol. 1 (2000), W.B. Saunders Company, Philadelphia 511-521
13. Hashizoe M., Ogura Y., Kimura H., Moritera T., Honda Y., Kyo M., Hyon S.-H., and Ikada Y. Scleral plug of biodegradable polymers for controlled drug release in the vitreous. Arch. Ophthalmol. 112 (1994) 1380-1384
14. Jonas J.B., Degenring R.F., Kreissig I., Akkoyun I., and Kamppeter B.A. Intraocular pressure elevation after intravitreal triamcinolone acetonide injection. Ophthalmology 112 (2005) 593-598
15. Jonas J.B., Kreissig I., and Degenring R. Intravitreal triamcinolone acetonide for treatment of intraocular proliferative, exudative, and neovascular diseases. Prog. Retin. Eye Res. 24 (2005) 587-611
16. Kato A., Kimura H., Okabe K., Okabe J., Kunou N., and Ogura Y. Feasibility of drug delivery to the posterior pole of the rabbit eye with an episcleral implant. Invest. Ophthalmol. Vis. Sci. 45 (2004) 238-244
17. Kunou N., Ogura Y., Yasukawa T., Kimura H., Miyamoto H., Honda Y., and Ikada Y. Long-term sustained release of ganciclovir from biodegradable scleral implant for the treatment of cytomegalovirus retinitis. J. Control. Release 68 (2000) 263-271
18. Lee S.Y., Chee S.P., Balakrishnan V., Farzavandi S., and Tan D.T. Surodex in paediatric cataract surgery. Br. J. Ophthalmol. 87 (2003) 1424-1426
19. McGhee C.N., Dean S., and Danesh-Meyer H. Locally administered ocular corticosteroids: benefits and risks. Drug Saf. 25 (2002) 33-55
20. Miyake K., Masuda K., Shirato S., Oshika T., Eguchi K., Hoshi H., Majima Y., Kimura W., and Hayashi F. Comparison of diclofenac and fluorometholone in preventing cystoid macular edema after small incision cataract surgery: a multicentered prospective trial. Jpn. J. Ophthalmol. 44 (2000) 58-67
21. Okabe J., Kimura H., Kunou N., Okabe K., Kato A., and Ogura Y. Biodegradable intrascleral implant for sustained intraocular delivery of betamethasone phosphate. Invest. Ophthalmol. Vis. Sci. 44 (2003) 740-744
22. Parke D.W. Intravitreal triamcinolone and endophthalmitis. Am. J. Ophthalmol. 136 (2003) 918-919
23. Rana Z.A., and Pearson P.A. Pharmacologic treatment in diabetic macular edema. In: Jaffe G.J., Ashton P., and Pearson P.A. (Eds). Intraocular Drug Delivery (2006), Taylor & Francis Group, New York 291-300
24. Sakurai E., Nozaki M., Okabe K., Kunou N., Kimura H., and Ogura Y. Scleral plug of biodegradable polymers containing tacrolimus (FK506) for experimental uveitis. Invest. Ophthalmol. Vis. Sci. 44 (2003) 4845-4852
25. Simone J.N., and Whitacre M.M. Effects of anti-inflammatory drugs following cataract extraction. Curr. Opin. Ophthalmol. 12 (2001) 63-67
26. Siqueira R.C., Filho E.R., Fialho S.L., Lucena L.R., Filho A.M., Haddad A., Jorge R., Scott I.U., and Cunha A.S. Pharmacokinetic and toxicity investigations of a new intraocular lens with a dexamethasone drug delivery system: a pilot study. Ophthalmologica 220 (2006) 338-342
27. Tan D.T., Chee S.P., Lim L., and Lim A.S. Randomized clinical trial of a new dexamethasone delivery system (Surodex) for treatment of post-cataract surgery inflammation. Ophthalmology 106 (1999) 223-231
28. Tan D.T., Chee S.P., Lim L., Theng J., and Van Ede M. Randomized clinical trial of Surodex steroid drug delivery system for cataract surgery: anterior versus posterior placement of two Surodex in the eye. Ophthalmology 108 (2001) 2172-2181
29. Taylor H.R., and Keeffe J.E. World blindness: a 21st century perspective. Br. J. Ophthalmol. 85 (2001) 261-266
30. Theng J.T., Ti S.E., Zhou L., Lam K.W., Chee S.P., and Tan D. Pharmacokinetic and toxicity study of an intraocular cyclosporine DDS in the anterior segment of rabbit eyes. Invest. Ophthalmol. Vis. Sci. 44 (2003) 4895-4899
31. Tojo K., and Isowaki A. Pharmacokinetic model for in vivo/in vitro correlation of intravitreal drug delivery. Adv. Drug Deliv. Rev. 52 (2001) 17-24
32. Wadood A.C., Armbrecht A.M., Aspinall P.A., and Dhillon B. Safety and efficacy of a dexamethasone anterior segment drug delivery system in patients after phacoemulsification. J. Cataract Refract. Surg. 30 (2004) 761-768
33. Wang J.J., Klein R., Smith W., Klein B.E., Tomany S., and Mitchell P. Cataract surgery and the 5-year incidence of late-stage age-related maculopathy: pooled findings from the Beaver Dam and Blue Mountains eye studies. Ophthalmology 110 (2003) 1960-1967
34. Wright P.L., Wilkinson C.P., Balyeat H.D., Popham J., and Reinke M. Angiographic cystoid macular edema after posterior chamber lens implantation. Arch. Ophthalmol. 106 (1988) 740-744
35. Yasukawa T., Kimura H., Tabata Y., Miyamoto H., Honda Y., and Ogura Y. Sustained release of cis-hydroxyproline in the treatment of experimental proliferative vitreoretinopathy in rabbits. Graefes Arch. Clin. Exp. Ophthalmol. 240 (2002) 672-678
36. Yasukawa T., Ogura Y., Sakurai E., Tabata Y., and Kimura H. Intraocular sustained drug delivery using implantable polymeric devices. Adv. Drug Deliv. Rev. 57 (2005) 2033-2046
37. Zhou T., Lewis H., Foster R.E., and Schwendeman S.P. Development of a multiple-drug delivery implant for intraocular management of proliferative vitreoretinopathy. J. Control. Release 55 (1998) 281-295